stockportfolio.pro
Stocks / CYTK vs UHS
CYTK vs UHS
Cytokinetics, Incorporated and Universal Health Services, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Cytokinetics, Incorporated (CYTK) | Universal Health Services, Inc. (UHS) | |
|---|---|---|
| Market cap | $9.1B | $8.9B |
| Revenue (latest FY) | $88.04M | $17.36B |
| Net income (latest FY) | $-784.96M | $1.49B |
| Revenue growth (5y CAGR) | 9.5% | 8.5% |
| Net margin | -891.6% | 8.6% |
| Return on equity | 119.0% | 20.5% |
| P/E ratio | — | 6.1 |
| Dividend yield | — | 0.6% |
| Profitable years (of last 10) | 1 | 10 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CYTK — free Open UHS — freeFrequently asked questions
Which is bigger, CYTK or UHS?
Cytokinetics, Incorporated is larger by market capitalization — $9.1B versus $8.9B.
Which grows faster, CYTK or UHS?
Over the last five fiscal years, Cytokinetics, Incorporated grew revenue faster — 9.5%/yr versus 8.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.